Status:
COMPLETED
Treatment Patterns and Clinical Outcomes Among Patients Receiving Palbociclib Combinations for Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2 ) Advanced/Metastatic Breast Cancer in the Arabian Gulf Region
Lead Sponsor:
Pfizer
Conditions:
Breast Neoplasms
Eligibility:
All Genders
18+ years
Brief Summary
retrospective non-interventional study (NIS) that aims to describe the demographics, clinical characteristics, clinical outcomes, and treatment patterns, among patients receiving palbociclib for the t...
Eligibility Criteria
Inclusion
- Age ≥18 years old.
- HR+/HER2- BC diagnosis with confirmed metastatic/locally advanced disease.
- Patient initiated on palbociclib (regardless the line of therapy) within the period between 01st January 2015 and 01st March 2019.
- Minimum of six months of follow up data since palbociclib initiation.
- Received palbociclib plus aromatase inhibitor or palbociclib plus fulvestrant in line with the licensed indication(s).
Exclusion
- Prior or current enrolment in an interventional clinical trial for metastatic/locally advanced BC.
- Patients who were initiated on palbociclib after 01st March 2019.
Key Trial Info
Start Date :
September 13 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 27 2022
Estimated Enrollment :
258 Patients enrolled
Trial Details
Trial ID
NCT04916509
Start Date
September 13 2021
End Date
December 27 2022
Last Update
June 6 2023
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
Hamad Medical Corporation
Doha, Qatar
2
King Abdulaziz Medical City National Guard Hospital
Jeddah, Saudi Arabia, 22384
3
King Abdulaziz Medical City National Guard Hospital Riyahd
Riyadh, Saudi Arabia, 11426
4
King Saud University Medical City Riyadh PO BOX 7805
Riyadh, Saudi Arabia, 11472